Pharmaceutical ETF shares increased this month, boosting market confidence

Data show that from the beginning of November to November 18, the share of 602 statistically available stock ETFs increased by 4.
197 billion as a whole, but industry ETFs also diverged, among which the share of ETFs in pharmaceutical, new energy, semiconductor and other industries increased significantly
.
In the pharmaceutical industry, E Fund's CSI 300 Healthcare ETF performed well, with an increase of 1.
329 billion shares as of November 18, including a record high on November 17, exceeding 30 billion shares for the first time to reach 30.
056 billion
.
The fund manager of the fund is E Fund, which owns 307 funds, with a total of 67 fund managers and a management scale of 170 million yuan
.
The fund manager is Yu Haiyan, who has been the fund manager of E Fund CSI 300 Pharmaceutical and Health Trading Open-ended Index Securities Investment Fund since September 23, 2013, and historical data shows that Yu Haiyan manages a total of 15 funds with a total fund size of 1,706.
819 billion yuan
.
In addition, the share of the Yongying CSI All Index Medical Device ETF has also increased this month, and the ETF is currently 1.
067 billion yuan
.
It is reported that the current fund manager of the public fund is Wan Chun, and his fund products include: Yongying Huize for one year, managed from July 1, 2019 to the present, with a return of 38.
04% during the period; Yongying CSI 300A, managed from July 17, 2019 to present, with a return of 23.
61%; Winwin ChiNext Index Initiation A, managed from September 16, 2019 to present, with a return of 56.
63%; Yongying CSI 300 ETF, managed from April 13, 2020 to present, with a yield of 25.
62%
during the period.
In the case of an increase in the share of ETFs in the pharmaceutical industry, to a certain extent, it can be seen that funds are optimistic about the pharmaceutical sector, which will help boost market confidence
.
Recently, institutional confidence in the market has also rebounded
.
For example, Ping An Fund believes that there are inflection point signals in both domestic and foreign policies, and recommends investors to enhance their confidence in the market; The fund manager of Yinhua Fund believes that in the medium term, it will mainly focus on industries with room for valuation switching and strong policy certainty next year
.
As far as the pharmaceutical sector is concerned, the sector has rebounded significantly since the end of September, when the logic of the rise was that valuation repair + innovative medical devices were temporarily not included in the collective procurement, and the recent rise logic added "twenty" and pharmaceutical reserves
.
Last week, under the continuous catalyst of the news surface, the entire pharmaceutical sector performed outstandingly
.
Among them, Yiling Pharmaceutical, a leading enterprise in innovative traditional Chinese medicine, rose 6% as of November 18, and its intraday stock price hit a record high, with a total market value of more than 77 billion yuan
.
According to statistics, since September 26, the cumulative increase in the stock price of Yiling Pharmaceutical has doubled
.
Looking forward to the future market, China Commercial Fund believes that after more than a year of adjustment in the pharmaceutical sector, the overall risk has been fully released, and under the promotion of favorable policies, the rebound market will continue to deduce, optimistic about investment opportunities
in high-end medical equipment, innovative drugs, innovative vaccines and other segments.
Guojin Securities believes that the sustained marginal recovery of pharmaceutical policies is expected to catalyze the reversal of the pharmaceutical sector
.
At present, the pharmaceutical sector is at the bottom of historical valuation and fund allocation, and continues to be optimistic about the three major directions
of pharmaceutical innovation, pharmaceutical advanced manufacturing and pharmaceutical consumption.
Guohai Securities said that from a long-term perspective, the pharmaceutical industry itself has both growth, technology and consumption attributes, the pharmaceutical track slope is long and thick, with the accelerating trend of domestic aging, and the wave of new medical infrastructure emerging in the post-epidemic era, the certainty of demand in the pharmaceutical industry continues to strengthen and the value is highlighted
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.